- Home
- GME vs REVBW Comparison
GME vs REVBW Comparison
Compare GME & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GME
- REVBW
- Stock Information
- Founded
- GME 1996
- REVBW N/A
- Country
- GME United States
- REVBW United States
- Employees
- GME N/A
- REVBW 9
- Industry
- GME Electronics Distribution
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- GME Consumer Discretionary
- REVBW Health Care
- Exchange
- GME Nasdaq
- REVBW Nasdaq
- Market Cap
- GME 10.7B
- REVBW N/A
- IPO Year
- GME 2002
- REVBW 2020
- Fundamental
- Price
- GME $21.99
- REVBW $0.02
- Analyst Decision
- GME Sell
- REVBW
- Analyst Count
- GME 1
- REVBW 0
- Target Price
- GME $10.00
- REVBW N/A
- AVG Volume (30 Days)
- GME 5.2M
- REVBW N/A
- Earning Date
- GME 03-25-2025
- REVBW N/A
- Dividend Yield
- GME N/A
- REVBW N/A
- EPS Growth
- GME N/A
- REVBW N/A
- EPS
- GME 0.17
- REVBW N/A
- Revenue
- GME $4,334,000,000.00
- REVBW N/A
- Revenue This Year
- GME N/A
- REVBW N/A
- Revenue Next Year
- GME N/A
- REVBW N/A
- P/E Ratio
- GME $129.45
- REVBW N/A
- Revenue Growth
- GME N/A
- REVBW N/A
- 52 Week Low
- GME $9.95
- REVBW N/A
- 52 Week High
- GME $64.83
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- GME 31.39
- REVBW N/A
- Support Level
- GME $23.44
- REVBW N/A
- Resistance Level
- GME $25.16
- REVBW N/A
- Average True Range (ATR)
- GME 1.17
- REVBW 0.00
- MACD
- GME -0.22
- REVBW 0.00
- Stochastic Oscillator
- GME 1.76
- REVBW 0.00
About GME GameStop Corporation
GameStop Corp is a U.S. multichannel video game, consumer electronics, and services retailer. The company operates across Europe, Canada, Australia, and the United States. GameStop sells new and second-hand video game hardware, physical and digital video game software, and video game accessories, mainly through GameStop, EB Games, and Micromania stores and international e-commerce sites. The majority of sales are from the United States.
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).